Research Topics
Genomes and GenesSpecies | Camillo PortaSummaryAffiliation: University of Pavia Country: Italy Publications
| Collaborators
|
Detail Information
Publications
From the Zeno's paradoxes to novel immunotherapeutic agents for kidney cancer: moving from an era of wrong premises and conclusions to a better comprehension of immunologyCamillo Porta
I R C C S San Matteo University Hospital Foundation, Medical Oncology, Piazzale C Golgi 19, 27100 Pavia, Italy 39 0382 501355 39 0382 501223
Expert Opin Biol Ther 13:813-5. 2013..From this well known paradox, it appears clearly that from wrong premises come wrong conclusions, something that for years has affected our perception of the role of immunotherapy in kidney cancer...- Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patientsCamillo Porta
Medical Oncology, I R C C S San Matteo University Hospital Foundation, Pavia, Italy
Oncology 84:115-22. 2013.... - Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreementC Porta
Medical Oncology, IRCCS San Matteo University Hospital Foundation, Piazzale C Golgi 19, I 27100 Pavia, Italy
Med Oncol 29:1896-907. 2012..Until additional data are available, consideration of patient response and tolerability to treatment may facilitate current decision-making regarding when to switch and which treatment to switch to in real-life clinical practice... - Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical reviewCamillo Porta
Medical Oncology, I R C C S San Matteo University Hospital Foundation, Piazzale C Golgi 19, I 27100 Pavia, Italy
Crit Rev Oncol Hematol 82:323-37. 2012..In conclusion, novel therapies used in combination or sequentially have potential to provide optimised treatment and patient outcomes in mRCC. The results from ongoing/planned trials are expected to help shape future therapy... - Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 TrialCamillo Porta
IRCCS San Matteo University Hospital Foundation, Pavia, Italy
Eur Urol 61:826-33. 2012..An understanding of the efficacy and safety of targeted agents in elderly patients with mRCC is essential to provide individualized therapy... - Sorafenib tosylate in advanced kidney cancer: past, present and futureCamillo Porta
Medical Oncology and Laboratory of Pre Clinical Oncology and Developmental Therapeutics, IRCCS San Matteo University Hospital, Piazzale C Golgi, Pavia, Italy
Anticancer Drugs 20:409-15. 2009.... 
Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patientsCamillo Porta
Medical Oncology, I R C C S San Matteo University Hospital, Piazzale C Golgi, I 27100 Pavia, Italy
Oncol Rep 13:689-95. 2005....- Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patientsCamillo Porta
Medical Oncology, I R C C S San Matteo University Hospital, Piazzale C Golgi, I 27100 Pavia, Italy
Lung Cancer 48:429-34. 2005..57%), while the other 10 patients (71.42%) progressed despite treatment. Median time to progression (TTP) was 8 weeks (average: 9.85, range: 7-20), while median overall survival was just 14 weeks (average: 21.69, range: 9-66+)... - Immunological stress in kidney cancer patients undergoing either open nephrectomy or nephron-sparing surgery: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cellsCamillo Porta
Medical Oncology, I R C C S San Matteo University Hospital Foundation, I 27100 Pavia, Italy
Oncol Rep 20:1511-9. 2008.... - Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinibC Porta
Medical Oncology, IRCCS San Matteo University Hospital Foundation, Piazzale C Golgi, I 27100, Pavia, Italy
Clin Exp Med 7:127-34. 2007.... - Circulating interleukin-6 as a tumor marker for hepatocellular carcinomaC Porta
Internal Medicine and Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia, Italy
Ann Oncol 19:353-8. 2008..A large amount of evidence suggests a possible role of interleukin-6 (IL-6) in the pathogenesis of hepatocellular carcinoma (HCC)... - Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancerCamillo Porta
Medical Oncology and Laboratory of Preclinical Oncology and Developmental Therapeutics, IRCCS San Matteo University Hospital, Piazzale Camillo Golgi, 2I 27100 Pavia, Italy
Expert Rev Anticancer Ther 6:141-52. 2006..The rationale of this treatment, its immunological and clinical results, as well as its pitfalls and perspectives, will be presented and discussed in this review... - Autoimmunity in thrombotic thrombocytopenic purpuraCamillo Porta
A Ferrata Institute of Internal Medicine and Medical Oncology, I R C C S San Matteo University Hospital, Pavia, Italy
Semin Thromb Hemost 31:633-40. 2005.... - Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest GroupC Porta
IRCCS San Matteo University Hospital, 27100 Pavia, Italy
Med Lav 96:360-9. 2005.... - Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agentsCamillo Porta
Medical Oncology, I R C C S San Matteo University Hospital Foundation, Pavia, Italy
ScientificWorldJournal 7:837-49. 2007..g., the use of Interleukin-2 in patients with high CAIX expression), while new trials are ongoing to test immunotherapy in combination with molecularly targeted agents, such as Sorafenib, Sunitinib, or Bevacizumab... - Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II studyCamillo Porta
Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientificio San Matteo University Hospital, Pavia, Italy
Cancer 100:2132-8. 2004..In the current Phase II study, the authors explored the antitumor activity of a combination of gemcitabine and oxaliplatin (L-OHP) in this setting... - Treating the individual: The need for a patient-focused approach to the management of renal cell carcinomaCamillo Porta
IRCCS San Matteo University Hospital Foundation, Pavia, Italy
Cancer Treat Rev 36:16-23. 2010..We recommend the integration of this approach into everyday clinical practice... - Impaired bone marrow hematopoietic progenitor cell function in rheumatoid arthritis patients candidated to autologous hematopoietic stem cell transplantationC Porta
Istituto di Medicina Interna ed Oncologia Medica, Università degli Studi di Pavia e I R C C S Policlinico San Matteo, Pavia, Italy
Bone Marrow Transplant 33:721-8. 2004..These observations may identify the biological risk factors for impaired mobilization and/or engraftment when RA patients are candidates for autologous hematopoietic stem cell grafting... - The European Multidisciplinary Cancer Congress (ECCO 16, ESMO 36 and ESTRO 30)Camillo Porta
Medical Oncology, I R C C S San Matteo University Hospital Foundation, 19 Piazzale C Golgi, 27100 Pavia, Italy
Future Oncol 8:13-5. 2012.... - Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAFC Porta
Medicina Interna ed Oncologia Medica, Universita degli Studi di Pavia, IRCCS Policlinico San Matteo, 27100 Pavia, Italy
Haematologica 85:820-5. 2000.... - Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II studyC Porta
Medicina Interna ed Oncologia Medica A Ferrata, I R C C S Policlinico San Matteo and Università degli Studi di Pavia, I 27100 Pavia, Italy
Cancer Chemother Pharmacol 47:423-8. 2001..We report our experience of combined hepatic intraarterial and systemic chemotherapy in advanced colorectal cancer patients... - Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient casesCamillo Porta
IRCCS San Matteo University Hospital Foundation, Pavia, Italy
BJU Int 108:E250-7. 2011..To conduct a retrospective, multicentre, cohort analysis to assess the sequential use of the tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib... - Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinomaCamillo Porta
IRCCS San Matteo University Hospital Foundation, Pavia, Italy
Eur J Cancer 47:1287-98. 2011..Both clinicians and patients should be aware of the potential side-effects of everolimus and understand that these side-effects are manageable with standard care to optimise patient benefit... - Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximabCamillo Porta
Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy
Immunotherapy 3:487-90. 2011..Furthermore, it is now clear that monoclonal antibodies actively interact with the immune system and show significant immune-modulating effects per se. Further translation research on this issue is much needed... - Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?Camillo Porta
Internal Medicine and Medical Oncology, IRCCS San Matteo University Hospital, I 27100 Pavia, Italy
Lung Cancer 38:159-62. 2002.... 
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in ItalyCamillo Porta
Medical Oncology, I R C C S San Matteo University Hospital Foundation, Piazzale C, Golgi 19, 27100 Pavia, Italy
BMC Cancer 11:105. 2011..This study assessed safety and treatment patterns for these agents in a real-world clinical practice setting in Italy...- Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinibCamillo Porta
Medical Oncology, I R C C S San Matteo University Hospital Foundation, Pavia I 27100, Italy
Kidney Int 77:809-15. 2010..Our study shows that serum levels of VEGF and NGAL are significant predictors of progression-free survival in patients with renal cell carcinoma treated with sunitinib... - Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitorsCamillo Porta
Medical Oncology and Laboratory of Pre Clinical Oncology and Developmental Therapeutics, Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia, Italy
J Urol 182:2569-77. 2009..Disturbed activation of the PI3K/Akt pathway is associated with many human malignancies. We reviewed the available literature on PI3K/Akt and PI3K/Akt targeting drugs for renal cell carcinoma... - Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cellsCamillo Porta
A Ferrata Institute of Internal Medicine and Medical Oncology, I R C C S San Matteo University Hospital, Piazzale C Golgi, I 27100 Pavia, Italy
Anticancer Res 27:165-73. 2007..Renal cell carcinoma (RCC)-induced immune dysfunction in patients at first diagnosis was investigated... - Tolerability of first-line therapy for metastatic renal cell carcinomaCamillo Porta
Medical Oncology, IRCCS San Matteo University Hospital Foundation, Piazzale C Golgi 19, I 27100 Pavia, Italy
Cancer Treat Rev 35:297-307. 2009..Finally, the implications of the tolerability profiles of these agents for combination therapy and use in broader populations than those enrolled in trials are assessed... - Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factorSilvia Ferrari
Flow Cytometry and Cell Therapy Unit, IRCCS San Matteo University Hospital, 27100 Pavia, Italy
Cancer Immunol Immunother 52:359-66. 2003.... - Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patientsSilvia Ferrari
Flow Cytometry and Cell Therapy Unit, Medical Oncology, IRCCS San Matteo University Hospital, 2, P le Golgi, 27100 Pavia, Italy
Oncol Rep 14:113-20. 2005.... - The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinomaIlaria Imarisio
Medical Oncology, IRCCS San Matteo University Hospital Foundation, Piazzale Camillo Golgi 19, 27100 Pavia, Italy
Future Oncol 8:1051-7. 2012..To evaluate the effect of sorafenib on the glucose tolerance and diabetic status of patients with metastatic renal cell carcinoma (RCC) or advanced hepatocellular carcinoma (HCC)... - Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysisElisa Ferraris
Oncologia Medica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Tumori 95:542-4. 2009..However, patients must be carefully selected and monitored, since sorafenib administration unquestionably increases the risk of side effects in patients affected by several conditions... - Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinomaGiuseppe Procopio
Department of Medical Oncology, Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Veneziani 1, 20133 Milan, Italy
Expert Rev Anticancer Ther 12:1089-96. 2012.... - Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma: short term resultsGiulia Bertino
Department of Otolaryngology Head Neck Surgery, University of Pavia, IRCCS Policlinico S, Matteo Foundation, P le Golgi 2, 27100 Pavia, Italy
BMC Cancer 9:313. 2009..The aim of the present study was to evaluate the survival, efficacy and safety of a modified RADPLAT-like protocol using carboplatin instead of cisplatin... - Weekly taxanes in metastatic breast cancer (review)Matteo Zimatore
Medicina Interna e Oncologia Medica, Università e IRCCS Policlinico San Matteo, I 27100 Pavia, Italy
Oncol Rep 9:1047-52. 2002..Ongoing phase III trials will clarify the efficacy of the weekly administration schedules and will define their role in the treatment of the metastatic breast cancer... - Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patientsAndrea Sartore-Bianchi
Medical Oncology, I.R.C.C.S. San Matteo University Hospital, I-27100 Pavia, Italy
Oncol Rep 12:855-9. 2004.... - Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective studyChiara Paglino
Medical Oncology, IRCCS San Matteo University Hospital Foundation, Piazzale C Golgi 19, Pavia, I 27100 Pavia, Italy
Future Oncol 8:1605-12. 2012..Here, our experience in patients with non-clear cell kidney cancer treated as part of the sunitinib Expanded Access Program is reported... - Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-scienceCamillo Porta
Medical Oncology, IRCCS, San Matteo University Hospital Foundation, Piazzale C Golgi, 19, I 27100 Pavia, Italy
Expert Rev Anticancer Ther 12:1571-7. 2012.... - Surgery and target agents for renal cell carcinoma treatment: the path between proper interactionCarlo Ganini
Medical Oncology, I R C C S San Matteo University Hospital Foundation, Piazzale C Golgi 19, Pavia, Italy
Urologia 78:9-15. 2011..Once an orphan disease, it has undergone an impressive change in its natural history with an improvement in overall survival, thanks to the development of new target agents... - Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II studyMario Airoldi
Department of Medical Oncology, San Giovanni Antica Sede Hospital, Torino, Italy
Am J Clin Oncol 27:155-63. 2004..The concurrent administration of two drugs does not alter pharmacokinetic drug behavior compared with single-agent data... - Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic studySilvia Ferrari
Flow Cytometry and Cell Therapy Unit, Medical Oncology, I R C C S San Matteo University Hospital, Pavia, Italy
Oncol Rep 9:1107-13. 2002..This information should be considered when utilizing topotecan with other anticancer drugs in the adjuvant setting as well as when dose-intensification of topotecan with stem cell support is planned... - Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?Camillo Porta
1 Oncologia Medica, Fondazione I R C C S Policlinico San Matteo, Pavia, Italy
J Cancer 2:333-8. 2011.... - Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocolA Riccardi
Medicina Interna e Oncologia Medica, Universita and Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, 27100 Pavia, Italy
Eur J Cancer 39:31-7. 2003..These data indicate that patients who maintain SD during first-line chemotherapy have a prognosis similar to that of patients who attain a response. Only patients whose disease progresses have a distinctly worse outcome... - Strategies of medical treatment for metastatic breast cancer (Review)M Danova
Flow Cytometry and Cell Therapy Unit, IRCCS San Matteo University Hospital, I 27100 Pavia, Italy
Int J Oncol 19:733-9. 2001..Moreover, the present trend is to try to rationalize the therapeutic approach on the basis of biological parameters which are prognostic and predictive of treatment response... - A rapid D-dimer assay in patients presenting at the emergency room with suspected acute venous thrombosis: accuracy and relation to clinical variablesS Siragusa
Servizio Pronto Soccorso ed Accettazione, IRCCS Policlinico S Matteo, Piazzale Golgi 2, 27100 Pavia, Italy
Haematologica 86:856-61. 2001.... - Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patientsFrancesco Lodola
Department of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, Pavia, Italy
PLoS ONE 7:e42541. 2012..As oncogenesis may be associated to the capability of tumor cells to grow independently on Ca(2+) influx, it is important to assess whether SOCE regulates EPC-dependent angiogenesis also in tumor patients... - 3rd Pavia international symposium on advanced kidney cancerCamillo Porta
I R C C S San Matteo University Hospital Foundation, Medical Oncology, 27100 Pavia, Italy
Expert Opin Pharmacother 13:445-53. 2012.... - Sigmoid colon metastasis from sarcomatoid renal cell carcinomaRoberta Invernizzi
Department of Medical Oncology, IRCCS San Matteo University Hospital, Pavia, Italy
Tumori 92:246-8. 2006..Computed tomography showed marked disease progression and the patient died 3 weeks later. Sigmoid colon metastasis from a primary sarcomatoid renal cell carcinoma has never been described in the literature... - In vitro antioxidant properties of amifostine (WR-2721, Ethyol)F Marzatico
Universita degli Studi di Pavia, Dipartimento di Scienze Fisiologiche e Farmacologiche Cellulari e Molecolari, Sezione di Farmacologia e Biotecnologie Farmacologiche, Piazza Botta, 11, I 27100 Pavia, Italy
Cancer Chemother Pharmacol 45:172-6. 2000..Despite a growing number of reports strongly supporting amifostine's clinical efficacy, few authors have focused on the biochemical basis of amifostine's antioxidant activity... - Determination of free and total (free plus protein-bound) melatonin in plasma and cerebrospinal fluid by high-performance liquid chromatography with fluorescence detectionVittoria Rizzo
Dipartimento di Biochimica, Sezione Analisi Chimico Cliniche, IRRCS Policlinico San Matteo, Universita degli Studi di Pavia, 27100 Pavia, Italy
J Chromatogr B Analyt Technol Biomed Life Sci 774:17-24. 2002..23+/-2.22 and 7.40+/-5.68 pg/ml, respectively. Detection of MLT in CSF was 5.01+/-2.31 and 28.55+/-6.95 pg/ml for the free and total fraction, respectively... - Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patientsDaniele Santini
Department of Medical Oncology, University Campus Bio Medico of Rome, Rome, Italy
PLoS ONE 6:e19234. 2011..RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG... - Ranpirnase and its potential for the treatment of unresectable malignant mesotheliomaCamillo Porta
Medical Oncology and Laboratory of Pre Clinical Oncology and Developmental Therapeutics, I R C C S San Matteo University Hospital Foundation, Pavia, Italy
Biologics 2:601-9. 2008..Ranpirnase may thus find its niche in combination with doxorubicin for mesothelioma as a second-line therapy, where no standard of care presently exists... - Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenibCamillo Porta
Camillo Porta, Medical Oncology and Laboratory of Preclinical Oncology and Experimental Therapies, IRCCS San Matteo University Hospital Foundation, Pavia I 27100, Italy
World J Hepatol 2:103-13. 2010.... - Antioxidant enzymatic system and free radicals pathway in two different human cancer cell linesC Porta
Istituto di Terapia Medica, Universita degli Studi di Pavia, I R C C S Policlinico San Matteo, Italy
Anticancer Res 16:2741-7. 1996..The two lines behaved differently in response to the above treatments. These observations might be important in designing more specific cancer treatments... - Platelet agonists and calcium homeostasis in endothelial cells: possible role in the interaction of endothelium with hemostatic systemC Porta
Sezione di Medicina Interna ed Oncologia, Universita degli Studi di Pavia, IRCCS Policlinico San Matteo, Italy
Haematologica 83:610-5. 1998..We addressed the hypothesis that some platelet agonists and products of activation of the hemostatic system could determine Ca++ transients in a bovine pulmonary artery endothelial cell line (CPA-47)... - Cardiovascular, cerebrovascular, and respiratory changes induced by different types of music in musicians and non-musicians: the importance of silenceL Bernardi
Department of Internal Medicine, IRCCS S Matteo, University of Pavia, Pavia, Italy
Heart 92:445-52. 2006.... - Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesotheliomaAndrea Sartore Bianchi
Institute of Internal Medicine and Medical Oncology, IRCCS Policlinico San Matteo University Hospital, 1 27100 Pavia corrected Italy
Clin Cancer Res 13:5942-51. 2007..We aimed at verifying whether the proteasome inhibitor Bortezomib could abrogate NF-kappaB activity in MMe cells, leading to tumor cell death and may be established as a novel treatment for this aggressive neoplasm... - Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexedPietro Bertino
DISCAFF Department and DFBC Center, University of Piemonte Orientale A Avogadro, 28100 Novara, Italy
Thorax 62:690-5. 2007..A study was undertaken to assess whether imatinib alone or combined with chemotherapeutic agents may be effective for treating mesothelioma... - Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesotheliomaCamillo Porta
Cancer Chemother Pharmacol 59:149-50. 2007 - Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicinRobert G Gish
California Pacific Medical Center, San Francisco, CA 94115, USA
J Clin Oncol 25:3069-75. 2007..The study objective was to compare the overall survival (OS) of patients with unresectable or metastatic hepatocellular carcinoma (HCC) treated with nolatrexed (NOL) or doxorubicin (DOX)... - New agents in the management of advanced mesotheliomaNicholas J Vogelzang
Nevada Cancer Institute, Las Vegas, NV 89135, USA
Semin Oncol 32:336-50. 2005..Together with the newer drugs, rapidly emerging from the laboratory to be applied in the clinic, we have the hope of making further advances in the struggle against this disease... - Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II studySergio Palmeri
Department of Oncology, Division of Medical Oncology, University of Palermo, Palermo, Italy
Cancer 107:2898-905. 2006..To date, the standard treatment for patients who have carcinoma of unknown primary site has not been established... - Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008Camillo Porta
Eur Urol 53:1092-3. 2008 - Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell cloneMaria Teresa Valle
Servizio di Immunologia, , Ospedale San Martino, Genova, Italy
Int J Mol Med 11:161-7. 2003..Even though the role of TGF-beta in the promotion of MMe growth should be further and better defined, this effect should be considered when designing new therapeutical approaches aimed at improving the immune response to MMe... - SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposurePaola Cacciotti
Department of Medical Sciences, University of Piemonte Orientale A. Avogadro, Novara, Italy
Cancer Res 65:5256-62. 2005.... - The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factorPaola Cacciotti
Department of Medical Sciences, University of Piemonte Orientale A. Avogadro, Novara, Italy
Am J Respir Cell Mol Biol 26:189-93. 2002..These results offer the first evidence that SV40 can cause VEGF release in SV40-positive MM cells and that entire viral genome is required for this effect... - Sorafenib in advanced hepatocellular carcinomaJosep M Llovet
Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
N Engl J Med 359:378-90. 2008..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma... - Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialRobert J Motzer
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Lancet 372:449-56. 2008..We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy... - Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenograftsPietro Bertino
Department of Chemical, Food, Pharmaceutical and Pharmacological Sciences and Drug and Food Biotechnology Center, University of Piemonte Orientale A Avogadro, Novara, Italy
Clin Cancer Res 14:541-8. 2008..We previously showed that imatinib mesylate synergizes with gemcitabine and pemetrexed in PDGFRbeta-positive mesothelioma cells. Here, we aimed at investigating these combined treatments in a novel mesothelioma model...